As a result, the median overall survival (OS) of metastatic HER2-positive breast cancer patients has reached 56 months.1 Despite effective new agents, metastatic breast cancer remains incurable since the tumours eventually acquire resistance to the agents. The gene discussed is ERBB2; the disease is neoplasm.